[{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"CBC Group","pharmaFlowCategory":"D","amount":"$315.0 million","upfrontCash":"Undisclosed","newsHeadline":"CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hasten Biopharmaceutic","amount2":0.32000000000000001,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.32000000000000001,"dosageForm":"Tablet","sponsorNew":"Hasten Biopharmaceutic \/ CBC Group","highestDevelopmentStatusID":"12","companyTruncated":"Hasten Biopharmaceutic \/ CBC Group"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"LIB Therapeutics","pharmaFlowCategory":"D","amount":"$325.0 million","upfrontCash":"$20.0 million","newsHeadline":"LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Lerodalcibep","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Hasten Biopharmaceutic","amount2":0.33000000000000002,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.33000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LIB Therapeutics and Partner Hasten Biopharmaceuticals Announce Lerodalcibep Clinical Trial Application Acceptance by the Center for Drug Evaluation at the National Medical Products Administration in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Lerodalcibep","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Hasten Biopharmaceutic","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Hasten Biopharmaceutic","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"12","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Hasten Biopharmaceutic","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"13","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"}]